<DOC>
	<DOCNO>NCT00921154</DOCNO>
	<brief_summary>The purpose study compare pharmacokinetic bioavailability profile ( rate amount absorption bloodstream ) test formulation ivermectin solution 1 mg/ml market reference formulation ivermectin 3 mg tablet take overnight fast .The study design accordance EU Note Guidance Investigation Bioavailability Bioequivalence 2001 .</brief_summary>
	<brief_title>Ivermectin Solution Bioequivalence Study - Fasted</brief_title>
	<detailed_description>Ivermectin antiparasitic medicine ( i.e . medicine use eliminate parasitic worm ) oral administration , approve US country tablet form . A new liquid formulation ivermectin develop facilitate dosing . This single dose , randomise , crossover study healthy adult male female volunteer , dose take overnight fast . Doses separate washout period least 14 day . Twenty-one blood sample take volunteer 144 hour period . Concentrations ivermectin plasma measure use validated chromatographic assay ( LC-MS/MS ) . Standard pharmacokinetic parameter obtain bioequivalence basis rate extent drug absorption assess .</detailed_description>
	<mesh_term>Ivermectin</mesh_term>
	<criteria>BMI &lt; = 30 kg/m2 Weight 50 90 kg Nonsmokers , smoker fewer 10 cigarette per day Clinically normal medical history physical exam finding Negative screen result protocolspecified drug abuse Negative HIV Hepatitis B C test Appropriate use contraception negative pregnancy test Ability comprehend communicate effectively investigative staff Ability give write informed consent pregnant nursing subject subject lived region endemic certain parasitic worm disease protocolspecified vital sign medical history would preclude participation trial , include , limited recent blood donation ( loss ) positive screen HIV , Hepatitis B , Hepatitis C Any indication current previous abuse alcohol , solvent drug Intake grapefruit product within 7 day start study Intake methylxanthinecontaining beverage within 24 hour prior study period quantity methylxanthine alcoholcontaining beverage , opinion Investigator abnormal ( 5 cup glass tea , coffee , cola , chocolate etc . per day 20 g alcohol/day ) Patients know suspected intestinal helminth infection Patients know hypersensitivity component Ivermectin product . Smoking alcohol consumption great protocolspecified level Protocolspecified contraindication blood sample Acute chronic medical , dietary psychiatric condition laboratory abnormality may increase risk associate trial participation investigational product administration may interfere interpretation trial result , judgment investigator , would make subject inappropriate entry trial</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>October 2011</verification_date>
	<keyword>therapeutic equivalency</keyword>
	<keyword>pharmacokinetics</keyword>
	<keyword>fast</keyword>
	<keyword>Healthy Volunteers</keyword>
</DOC>